JP2025084754A5 - - Google Patents

Info

Publication number
JP2025084754A5
JP2025084754A5 JP2025016270A JP2025016270A JP2025084754A5 JP 2025084754 A5 JP2025084754 A5 JP 2025084754A5 JP 2025016270 A JP2025016270 A JP 2025016270A JP 2025016270 A JP2025016270 A JP 2025016270A JP 2025084754 A5 JP2025084754 A5 JP 2025084754A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hypnotic
nri
muscle relaxant
release formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025016270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025084754A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/017323 external-priority patent/WO2020163785A1/en
Application filed filed Critical
Publication of JP2025084754A publication Critical patent/JP2025084754A/ja
Publication of JP2025084754A5 publication Critical patent/JP2025084754A5/ja
Pending legal-status Critical Current

Links

JP2025016270A 2019-02-08 2025-02-03 睡眠時無呼吸を治療するための方法および組成物 Pending JP2025084754A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962803223P 2019-02-08 2019-02-08
US62/803,223 2019-02-08
PCT/US2020/017323 WO2020163785A1 (en) 2019-02-08 2020-02-07 Methods and compositions for treating sleep apnea
JP2021546285A JP7705348B2 (ja) 2019-02-08 2020-02-07 睡眠時無呼吸を治療するための方法および組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021546285A Division JP7705348B2 (ja) 2019-02-08 2020-02-07 睡眠時無呼吸を治療するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2025084754A JP2025084754A (ja) 2025-06-03
JP2025084754A5 true JP2025084754A5 (https=) 2025-10-24

Family

ID=71947080

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021546285A Active JP7705348B2 (ja) 2019-02-08 2020-02-07 睡眠時無呼吸を治療するための方法および組成物
JP2025016270A Pending JP2025084754A (ja) 2019-02-08 2025-02-03 睡眠時無呼吸を治療するための方法および組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021546285A Active JP7705348B2 (ja) 2019-02-08 2020-02-07 睡眠時無呼吸を治療するための方法および組成物

Country Status (17)

Country Link
US (1) US12558327B2 (https=)
EP (2) EP3920898B1 (https=)
JP (2) JP7705348B2 (https=)
KR (1) KR20210125507A (https=)
CN (2) CN118557736A (https=)
AU (2) AU2020219809B2 (https=)
BR (1) BR112021015600A2 (https=)
CA (1) CA3129270A1 (https=)
EA (1) EA202192202A1 (https=)
ES (1) ES3049086T3 (https=)
IL (1) IL285197A (https=)
MX (2) MX2021009407A (https=)
MY (1) MY210043A (https=)
PH (1) PH12021551850A1 (https=)
SG (1) SG11202108225QA (https=)
UA (1) UA130366C2 (https=)
WO (1) WO2020163785A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102874891B1 (ko) 2018-01-30 2025-10-21 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 방법 및 조성물
CN118557736A (zh) 2019-02-08 2024-08-30 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物
WO2022204228A1 (en) * 2021-03-24 2022-09-29 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
US20240277719A1 (en) * 2021-06-17 2024-08-22 Apnimed, Inc. (Delaware) Norepinephrine reuptake inhibitors for treating sleep apnea
EP4522149A1 (en) * 2022-05-13 2025-03-19 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
KR20250057804A (ko) * 2022-09-02 2025-04-29 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 방법 및 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU767877B2 (en) 1999-05-20 2003-11-27 Sepracor, Inc. Methods for treatment of asthma using S-oxybutynin
PT1257277E (pt) 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc Novas combinacoes de farmacos
US20020155113A1 (en) 2001-03-13 2002-10-24 Miyoung Chun Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US20040235925A1 (en) 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20070219201A1 (en) 2004-05-27 2007-09-20 Warner-Lambert Company Llc Combination of atomoxetine and a 5ht1a receptor agonist for treating adhd and other disorders
US20060039866A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
EP1827450A4 (en) * 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
CN101132777A (zh) 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
PL2083811T3 (pl) 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
WO2008122019A1 (en) 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
EP2142183A2 (en) * 2007-04-09 2010-01-13 Sepracor Inc. Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
AR069875A1 (es) 2007-12-21 2010-02-24 Eurand Inc Composiciones de temazepam para tabletas de desintegracion oral y metodo de preparacion
US20100204058A1 (en) 2009-01-28 2010-08-12 Howard Yuan-Hao Chang Profiling for Determination of Response to Treatment for Inflammatory Disease
JP2014503593A (ja) 2011-01-28 2014-02-13 ファンタスティック・メディカル・リサーチ・インスティテュート・エルエルシー 閉塞性睡眠時無呼吸を処置するための方法
US20170304286A1 (en) 2014-10-24 2017-10-26 Launx Biomedical Co., Ltd. New indication of paroxetine pharmaceutical composition for treating cancer
MX373319B (es) * 2015-04-27 2020-06-13 Arena Pharm Inc Derivados de hexahidro-[1-4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor.
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
ES2925951T3 (es) * 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
GEAP202416602A (en) 2017-04-28 2024-10-10 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
KR102874891B1 (ko) 2018-01-30 2025-10-21 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 방법 및 조성물
CN118557736A (zh) 2019-02-08 2024-08-30 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物

Similar Documents

Publication Publication Date Title
JP2025084754A5 (https=)
JP2022519721A5 (https=)
JP2023139000A5 (https=)
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
US10166207B2 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
AU2006252051B2 (en) Orodispersible Pharmaceutical Composition for Oromucosal or Sublingual Administration of Agomelatine
CN101132777A (zh) 用于睡眠障碍的药物组合物
JP2008524332A5 (ja) 睡眠障害のための医薬組成物
CN104168895A (zh) 包含西地那非作为活性成分的掩蔽苦味的高含量快速溶解膜
AU2003299723A1 (en) Compositions and methods for treating upper respiratory congestion
BR112019027286A2 (pt) formulação de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva
JP2022506113A5 (https=)
CN104379138B (zh) 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合
CN101460144A (zh) AchE-NMDA组合物干胶片
JP2022548787A (ja) 治療用製剤およびその使用
US8748489B2 (en) Solid pharmaceutical composition containing a combination of an intestinal motility regulating agent and an antiflatulent
TW200534852A (en) 4-methylpyrazole formulations for inhibiting ethanol intolerance
JP7270958B2 (ja) 低中毒性抗コリン作動性エステルのための方法および組成物
CN110650732A (zh) 锭剂剂型
CN102600277A (zh) 一种含有巴戟天提取物的药用组合物
JP2024523876A5 (https=)
JP2024511091A5 (https=)
US20180318228A1 (en) Method for a slow release of drugs from orally dissolving capsules
CN101198327A (zh) 治疗半夜失眠的固体组合物和方法
JP2024531799A5 (https=)